Healthy volunteers
Conditions
Interventions
Group 1: 1g/kg body mass glucose supplementation prior to exercise
Group 2: 1g/kg body mass fructose supplementation prior to exercise
Group 3: 1g/kg body mass glucose and fructose (0.5g each) supplem
Sponsors
Universität BayreuthInstitut für SportwissenschaftenDivision of Exercise Physiology and Metabolism
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: - Informed consent obtained - Male or female aged 18–65 years (both inclusive) - Body mass index 18.0–29.9 kg/m2 (both inclusive) - Body Mass specific oxygen uptake >20 ml/min/Kg-1 (VO2max) - Sufficient lower- and upper body strength to conduct movements in leg press and chest press exercise (100% BM leg-press and 30%/75% BM chest-press) - Normal glucose tolerance (measured via overnight fasting blood glucose levels)
Exclusion criteria
Exclusion criteria: - Enrolment in other study - Known or suspected hypersensitivity to trial product(s) or related products - Receipt of any investigational medicinal product within 1 week prior to screening in this trial - Suffer from or history of a life-threatening disease (i.e. cancer judged not to be in full remission except basal cell skin cancer or squamous cell skin cancer), or clinically severe diseases that directly influence the study results, as judged by the Investigator. This does not prohibit the participation of patients taking medications that influences the metabolism (e.g. statin) or cardio-respiratory system (e.g. asthma spray) as long as the therapy is stable and is not adapted throughout the run of the trial. Furthermore, it does not excluded patients how have celiac disease (or similar diseases or allergies), as long as the disease is stable, and patients are able to stay on their specific (e.g.) gluten-free diet. - Participant with a heart rate <35 beats per minute (bpm) at screening (after resting for 5 min in supine position) - Supine blood pressure at screening (after resting for 5 min in supine position) outside the range of 90-150 mmHg for systolic or 50-95 mmHg for diastolic (excluding white-coat hypertension; therefore, if a repeated measurement on a second screening Visit shows values within the range, the participant can be included in the trial). This exclusion criterion also pertains to participants being on anti-hypertensives - Significant abnormal ECG at screening, as judged by the Investigator - Any chronic (metabolic) disorder or severe disease which, in the opinion of the Investigator might jeopardise participant’s safety or compliance with the protocol - History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction - Participant with mental incapacity or language barriers precluding adequate understanding or cooperation or who, in the opinion of their general practitioner or the Investigator, should not participate in the trial - Any condition that would interfere with trial participation or evaluation of results, as judged by the Investigator - Female of childbearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods (adequate contraceptive measures include sterilisation, hormonal intrauterine devices, oral contraceptives, sexual abstinence or vasectomised partner).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time in minutes/seconds until exhaustion following the ingestion of glucose and/or fructose or sucralose beverages during cycling exercises at 20% above lactate turn point 2 (LTP2) | — |
Secondary
| Measure | Time frame |
|---|---|
| - RepetitionsLegpeak: Number of repetitions following the ingestion of study specific beverage at a body mass specific 100% body mass in Kg (BM) for male and 100% body mass in kg for female (BM) in leg-press. - RepetitionsChestpeak: Number of repetitions following the ingestion of study specific beverage of 75% body mass in Kg (BM) for male and 30% BM in kg for female in chest-press. - Glucosemeanstartcycl: Mean ± standard deviation and coefficient of variation of blood glucose level following ingestion of study specific beverage until the start of cycling exercise in comparison of trial arms - Glucosemeanendcycl: Mean ± standard deviation and coefficient of variation of blood glucose level following ingestion of study specific beverage in comparison of trial arms from ingestion from the start of cycling exercise until the end of cycling exercise - Glucosedeltastartleg: Mean ± standard deviation and coefficient of variation of blood glucose level following ingestion of study specific beverage in comparison of trial arms from ingestion until the start of legpress exercise - Glucosedeltaendleg: Mean ± standard deviation and coefficient of variation of blood glucose level following ingestion of study specific beverage in comparison of trial arms from ingestion from the start of legpress until the end of legpress - Glucosedeltastartchest: Mean ± standard deviation and coefficient of variation of blood glucose level following ingestion of study specific beverage in comparison of trial arms from ingestion until the start of chestpress exercise - Glucosedeltaendchest: Mean ± standard deviation and coefficient of variation of blood glucose level following ingestion of study specific beverage in comparison of trial arms from ingestion from the start of chestpress until the end of chestpress - Lactatepeak: Mean and Peak blood lactate level following ingestion of study specific beverage in comparison of trial arms - Lactatedelta Mean ± standard deviation and coefficient of va | — |
Countries
Germany
Contacts
Public ContactOthmar Moser
Division Exercise Physiology and Metabolism
Outcome results
None listed